HRD related signature 3 predicts clinical outcome in advanced tubo-ovarian high-grade serous carcinoma
Authors:
Open Access
- 6 December 2023
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 180, 91-98
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Homologous recombination deficiency and ovarian cancerEuropean Journal of Cancer, 2016
- Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancerNature Genetics, 2016
- BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancerAnnals of Oncology, 2016
- Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian CancerCancer Discovery, 2015
- Whole–genome characterization of chemoresistant ovarian cancerNature, 2015
- Germline and somatic mutations in homologous recombination genes predict platinum response and improved overall survival in ovarian, fallopian tube, and peritoneal carcinomasGynecologic Oncology, 2013
- Signatures of mutational processes in human cancerNature, 2013
- Allele-specific copy number analysis of tumorsProceedings of the National Academy of Sciences, 2010
- The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing dataGenome Research, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009